PROJECT DESCRIPTION
The Indian pharmaceutical sector has come a long way, being almost non-existent before 1970 to a prominent provider of healthcare products, meeting almost 95 per cent of the country's pharmaceuticals needs. The Industry today is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology. It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously.
Indian Pharma Industry is playing a key role in promoting and sustaining development in the vital field of medicines, besides this it boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world.
The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units. It has expanded drastically in the last two decades. The leading 250 pharmaceutical companies control 70% of the market, with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are about 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).
These units produce the complete range of pharmaceutical formulations, i.e., medicines ready for consumption by patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used for production of pharmaceutical formulations.
Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpower, strength of national laboratories and an increasing balance of trade. The Pharmaceutical Industry, with its rich scientific talents and research capabilities, supported by Intellectual Property Protection regime is well set to take on the international market.
Market Survey
The Indian pharmaceutical industry is the fourth largest in the world in terms of volume of output and thirteenth in domestic demand. However, the Indian industry, valued at USD 17 bn in represented just over 1% of the global pharmaceutical industry in value terms. The domestic market is estimated at Rs 680 bn.
According to a study by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of USD 25 bn (Rs 1200 bn) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing. Incidentally, according to another report by Associated Chamber of Commerce (ASSOCHAM) in India, the market is estimated to grow to more modest level of USD 9.5 bn in 2010).
India has the world's third largest active pharmaceutical ingredients (API) for the industry valued at a little less than USD 2 bn. Top 5 API producers account for approximately 6.5 %. The leading APIs are anti-infective, gastrointestinal, cardiovascular and respiratory drugs.
However, India's pharmaceutical industry might witness some decline in the number of smaller companies that either leave the market or are acquired by larger Indian or foreign companies. Since 2000, a number of smaller Indian pharmaceutical companies have, in fact, been acquired by larger companies. These cases include, among the more notable ones, Wockhardt's acquisition of Merind and Tata Pharma; Ranbaxy's purchase of Crosland; Nicholas Piramal's acquisition of Roche etc.
The Indian firms produce nearly 60,000 generic brands in 60 therapeutic categories and between 350 and 400 bulk drugs. India's drug market consists mainly of second and third generation drugs no longer subject to patent protection in the developed world. Although India is the world's leading producer of generic drugs, its annual per capita consumption of pharmaceuticals has been among the lowest placed approximately at USD 4.50 per person as compared to USD 820 in the United States and USD 13 in China.
The bulk drugs segment continues to be the highest revenue generating segment for the Indian pharma industry. It accounts for production worth Rs 120 bn and contributes about 36% of the total pharma exports. India produces 400 bulk drugs through its 1,300 licensed bulk drug units that cater to most of the domestic bulk drug requirements.
The key categories driving growth are the traditionally largest segment - anti-infective and gastro-intestinal, drugs, which expanded by 22% and 19% respectively. Fast sales growth is also visible in categories like respiratory (18%), cardiac (14%), neurology (20%) and anti-diabetic (19%). Anti-TB is the only category that has seen a decline in value and volume terms.
The number of product launches exceeds 2,000 annually. Both MNC and Indian companies are implementing strategies which will help them to benefit from and cope with the developing patent regime. Global pharma companies are increasingly exploring low cost option to outsource research and manufacturing, because of emerging slow-down in patented drug sales and high cost of R&D.
Indian pharmaceutical companies are in various stages of new drug discoveries. They have been scouting for global partners to help them in their goal. However, companies like Dr Reddy's Laboratories, Wockhardt’s, Glen mark Pharmaceuticals, Ranbaxy Laboratories, Orchid Chemicals and Lupin need financial and technical support from foreign pharmaceutical players to take their new drugs to the global market. Dr. Reddy's Laboratory (DRL) recently announced the beginning of Phase III clinical trials of its anti-diabetic drug Balagliatzone. Co-developed with Danish firm Rheoscience, the successful completion of the trial could give India its first intellectual property from the pharma sector.
India has the highest number of (US Food and Drug Administration) USFDA approved manufacturing facilities outside the US and this puts India in good position to export to regulated markets.
The major players in the country are:
Aanjaneya Lifecare Ltd.
Aashi Industries Ltd.
Abbott India Ltd.
Advik Laboratories Ltd.
Aesculapius Remedies Ltd.
Ajanta Pharma Ltd.
Albert David Ltd.
Alkem Laboratories Ltd.
Alpa Laboratories Ltd.
Ambalal Sarabhai Enterprises Ltd.
Amee Cosmo Pharma Ltd.
American Remedies Ltd.
Amstrin Healthcare Ltd.
Anan Drug & Chem Ltd.
Andre Laboratories Ltd.
Anglo-French Drugs & Inds. Ltd.
Ankur Drugs & Pharma Ltd.
Anmol Drugs & Pharmaceuticals Ltd.
Anuh Pharma Ltd.
Apex Laboratories Ltd.
Apple Laboratories Ltd.
Armour Chemicals Ltd.
Arvind Remedies Ltd.
Astrazeneca Pharma India Ltd.
Astron Drugs & Inds. Ltd.
Aurobindo Pharma Ltd.
Aventis Pharma Ltd.
B D H Industries Ltd.
Bafna Pharmaceuticals Ltd.
Bal Pharma Ltd.
Basav Chem Ltd.
Bassein Drugs Ltd.
Beem Healthcare Ltd.
Bengal Immunity Ltd.
Beryl Drugs Ltd.
Bharat Parenterals Ltd.
Bharat Serums & Vaccines Ltd.
Biddle Sawyer Ltd.
Bio-Ethicals Pharma Ltd.
Biocon Biopharmaceuticals Pvt. Ltd.
Biocon Ltd.
Biofil Chemicals & Pharmaceuticals Ltd.
Biological E. Ltd.
Blue Cross Laboratories Ltd.
Boehringer Mannheim India Ltd.
Brabourne Enterprises Ltd.
Bravo Healthcare Ltd.
Brawn Biotech Ltd.
Burroughs Wellcome (India) Ltd.
Cadila Healthcare Ltd.
Cadila Laboratories Pvt. Ltd.
Cadila Pharmaceuticals Ltd.
Caplin Point Laboratories Ltd.
Caryl Laboratories Ltd.
Casil Industries Ltd.
Celestial Biolabs Ltd.
Centaur Pharmaceuticals Pvt. Ltd.
Cepham Organics Ltd.
Cepham Pharmaceuticals Ltd.
Chemech Laboratories Ltd.
Chemosyn Ltd.
Ciba Ckd Biochem Ltd.
Claris Lifesciences Ltd.
Colinz Laboratories Ltd.
Combat Drugs Ltd.
Concept Pharmaceuticals Ltd.
Concord Biotech Ltd.
Concord Drugs Ltd.
Coral Laboratories Ltd.
Core Laboratories Ltd.
Cosme Farma Laboratories Ltd.
Cosme Pharma Ltd.
Creative Health Care Pvt. Ltd.
Croslands Research Laboratories Ltd.
Croydon Chemical Works Ltd.
Curewell (India) Ltd.
Damania Pharma Ltd.
Deepharma Laboratories Ltd.
Deepharma Ltd.
Dey'S Medical Stores Mfg. Ltd.
Dishman Pharmaceuticals & Chemicals Ltd.
Dolphin Laboratories Ltd.
Dr. Reddy'S Laboratories Ltd.
Druid Pharma Ltd.
Dujohn Laboratories Ltd.
Dumex Ltd.
Eaco Labs Ltd.
Earnest Healthcare Ltd.
East India Pharmaceutical Works Ltd.
Ebers Pharmaceuticals Ltd.
Elder Health Care Ltd.
Elder Pharmaceuticals Ltd.
Elder Projects Ltd.
Elvina Pharmaceuticals Ltd.
Emaai Pharma Ltd.
Emcure Pharmaceuticals Ltd.
Endo Labs Ltd.
Entod Pharmaceuticals Ltd.
Esskay Pharmaceuticals Ltd.
Ethnor Ltd.
Eupharma Laboratories Ltd.
Everest Organics Ltd.
Evid & Co. Chemicals Ltd.
F D C Ltd.
Fine Drugs & Chemicals Ltd.
Flamingo Pharmaceuticals Ltd.
Fredun Pharmaceuticals Ltd.
Fresenius Kabi Oncology Ltd.
Fulford (India) Ltd.
Geno Pharmaceuticals Ltd.
Gentech Laboratories Ltd.
Geoffrey Manners & Co. Ltd.
German Remedies Ltd.
Glaxosmithkline Pharmaceuticals Ltd.
Glen mark Exports Ltd.
Glen mark Generics Ltd.
Glen mark Laboratories Ltd.
Glen mark Pharmaceuticals Ltd.
Global Remedies Ltd.
Goa Antibiotics & Pharmaceuticals Ltd.
Group Pharmaceuticals Ltd.
Guardian Health Care Ltd.
Gufic Biosciences Ltd.
Gujarat Inject Ltd.
Gujarat Terce Laboratories Ltd.
Gujarat Themis Biosyn Ltd.
H O D Laboratories Ltd.
Hab Pharmaceuticals & Research Ltd.
Haffkine Ajintha Pharmaceuticals Ltd.
Hallmark Healthcare Ltd.
Harleystreet Pharmaceuticals Ltd.
Health Care Ltd.
Hexone Pharmaceuticals Ltd.
Hindustan Max-Gb Ltd.
Hub Pharmaceuticals Pvt. Ltd.
I D P L (Tamil Nadu) Ltd.
Icon Biopharma & Healthcare Ltd.
Icpa Health Products Ltd.
Idma Laboratories Ltd.
Ind-Swift Laboratories Ltd.
Ind-Swift Ltd.
India Infusion Ltd.
Indian Drugs & Pharmaceuticals Ltd.
Indoco Healthcare Ltd.
Indoco Remedies Ltd.
Indon Healthcare Ltd.
Innotech Pharma Ltd.
Intas Pharmaceuticals Ltd.
Intercare Limited
Intercare Ltd.
International Drug Co. Ltd.
Inventia Healthcare Pvt. Ltd.
Inwinex Pharmaceuticals Ltd.
Ipca Laboratories Ltd.
Ivee Injectaa Ltd.
J B Chemicals & Pharmaceuticals Ltd.
J K Pharmachem Ltd.
Jagsonpal Exports India Pvt. Ltd.
Jagsonpal Pharmaceuticals Ltd.
Jenburkt Pharmaceuticals Ltd.
Jilichem Laboratories (India) Ltd.
John Wyeth (India) Ltd.
Johnson & Johnson Ltd.
Kabra Drugs Ltd.
Kappac Pharma Ltd.
Karnataka Antibiotics & Pharmaceuticals Ltd.
Kee Pharma Ltd.
Kilitch Drugs (India) Ltd.
Konkan Capsules Ltd.
Krebs Biochemicals & Inds. Ltd.
Labinduss Ltd.
Lekar Healthcare Ltd.
Lekar Pharma Ltd.
Lincoln Pharmaceuticals Ltd.
Liva Healthcare Ltd.
Lordvin Labs Ltd.
Lupin Laboratories Ltd.
Lupin Ltd.
Lyka B D R International Ltd.
Lyka Labs Ltd.
Lympha Laboratories Ltd.
M J Pharmaceuticals Ltd.
Macleods Pharmaceuticals Ltd.
Maharashtra Antibiotics & Pharmaceuticals Ltd.
Makers Laboratories Ltd.
Maneesh Pharmaceuticals Ltd.
Manipur State Drugs & Pharmaceuticals Ltd.
Marck Biosciences Ltd.
Mars Life Sciences Ltd.
Martin & Harris Laboratories Ltd.
Max India Ltd.
Mayank & Lili Pharma Ltd.
Mayo (India) Ltd.
Mcneil & Argus Pharmaceuticals Ltd.
Medicamen Biotech Ltd.
Medispan Ltd.
Medley Pharmaceuticals Ltd.
Meghdoot Chemicals Ltd.
Meher Pharma (India) Ltd.
Merck Ltd.
Mercury Laboratories Ltd.
Mercury Phytochem Ltd.
Merind Ltd.
Mesco Pharmaceuticals Ltd.
Metropolitan Overseas Ltd.
Micro Labs Ltd.
Monarch Laboratories Ltd.
Morepen Laboratories Ltd.
Mount Mettur Pharmaceuticals Ltd.
N B Z Pharma Ltd.
N R Jet Enterprises Ltd.
Natco Pharma Ltd.
Nem Organics Ltd.
Neon Laboratories Ltd.
Nestor Pharmaceuticals Ltd.
Neulife Laboratories Ltd.
Nirma Ltd.
Nitya Laboratories Ltd.
Novartis India Ltd.
Novus Pharmaceuticals Ltd.
Om Pharmaceuticals Ltd.
Omega Biotech Ltd.
Omega Laboratories Ltd.
Onco Therapies Ltd.
Opec Innovations Ltd.
Orchid Chemicals & Pharmaceuticals Ltd.
Organon (India) Ltd.
Ozone Pharmaceuticals Ltd.
P C I Chemicals & Pharmaceuticals Ltd.
Paam Pharmaceuticals (Delhi) Ltd.
Panacea Biotec Ltd.
Parabolic Drugs Ltd.
Paras Pharmaceuticals Ltd.
Parke-Davis (India) Ltd.
Penam Laboratories Ltd.
Perk Pharmaceuticals Ltd.
Pfimex Pharmaceuticals Ltd.
Pfizer Ltd.
Phaarmasia Ltd.
Phar-East Laboratories Ltd.
Pharmacia Healthcare Ltd.
Pharmaids Pharmaceuticals Ltd.
Pharmax Corporation Ltd.
Pharmed Ltd.
Phyto Specialities Pvt. Ltd.
Plethico Pharmaceuticals Ltd.
Procter & Gamble Hygiene & Health Care Ltd.
Quality Pharmaceuticals Ltd.
R P G Life Sciences Ltd.
Rajasthan Drugs & Pharmaceuticals Ltd.
Rajat Pharmachem Ltd.
Ranbaxy Drugs Ltd.
Ranbaxy Laboratories Ltd.
Raptakos, Brett & Co. Ltd.
Ravish Infusions Ltd.
Reckitt Benckiser (India) Ltd.
Rekvina Laboratories Ltd.
Resonance Specialties Ltd.
Rhone-Poulenc (India) Ltd.
Rolex Pharmaceuticals Ltd.
Rosemount Pharma India Ltd.
Rubra Medicaments Ltd.
Rupal Chemical Inds. Ltd.
Rusan Pharma Ltd.
S A M Biotech Ltd.
Saket Projects Ltd.
Sandoz (India) Ltd. [Amalgamated]
Sanjeevanee Pharmaceuticals Ltd.
Sanjivani Paranteral Ltd.
Sanofi-Synthelabo (India) Ltd.
Sarabhai Piramal Pharmaceuticals Pvt. Ltd.
Sarala Pharmaceuticals Ltd.
Sarthi Pharmaceuticals Ltd.
Sarvodaya Labs Ltd.
Schering-Plough (India) Pvt. Ltd.
Senbo Industries Ltd.
Shalina Laboratories Pvt. Ltd.
Sharvani Pharmaceuticals Ltd.
Shiv Herbal Research Laboratory Ltd.
Sidmak Laboratories (India) Pvt. Ltd.
Sigma Laboratories Ltd.
Smith Stanistreet Pharmaceuticals Ltd.
Smithkline Beecham Pharmaceuticals (India) Ltd. [Amalgamated]
Solumiks Herbaceuticals Ltd.
Sri Chakra Remedies Ltd.
Sri Krishna Drugs Ltd.
Sri Krishna Pharmaceuticals Ltd.
Strides Arcolab Ltd.
Sun Pharmaceutical Inds. Ltd.
Surya Pharmaceutical Ltd.
Sustime Pharma Ltd.
Suyog Pharmaceuticals Pvt. Ltd.
Swega Laboratories Ltd.
Swet-Chem Antibiotics Ltd.
Syncom Formulations (India) Ltd.
Syncom Healthcare Ltd.
T K Healthcare Ltd.
Tablets (India) Ltd.
Tamilnadu Dadha Pharmaceuticals Ltd.
Targof Pure Drugs Ltd.
Taulis Pharma Ltd.
Teem Laboratories Ltd.
Themis Medicare Ltd.
Tonira Pharma Ltd.
Torrent Pharmaceuticals Ltd.
Toshvin Industries Ltd.
Trans Medicare Ltd.
Travel Co. In Pvt. Ltd.
Troika Pharmaceuticals Ltd.
Twilight Litaka Pharma Ltd.
U S V Ltd.
Uni-Sankyo Ltd.
Uni-Ucb Ltd.
Unibios Laboratories Ltd.
Unichem Laboratories Ltd.
Unicorn Pharmaceuticals (India) Ltd.
Unimark Remedies Ltd.
Unimed Investments Ltd.
Unimed Technologies Ltd.
Unique Pharmaceutical Laboratories Ltd.
Universal Generics Ltd.
Universal Pharmaceuticals Ltd.
Unjha Formulations Ltd.
Vellanova Pharmaceuticals Ltd.
Venkat Pharma Ltd.
Veronica Laboratories Ltd.
Vista Pharmaceuticals Ltd.
Vita Biopharma Pvt. Ltd.
Vysali Pharmaceuticals Ltd.
Wallace Pharmaceuticals Ltd.
Wander Pvt. Ltd.
Warren Pharmaceuticals Ltd.
Welcure Drugs & Pharmaceuticals Ltd.
White Way Products (Pharma) Ltd.
Win-Medicare Pvt. Ltd.
Wintac Ltd.
Wockhardt’s Ltd.
Wyeth Laboratories Ltd.
Wyeth Ltd.
Yogi Healthcare Ltd.
Zenith Health Care Ltd.
Zenotech Laboratories Ltd.
Zillion Pharmachem Ltd.
Zim Laboratories Ltd.
Zuventus Healthcare Ltd.
Zydus Animal Health Ltd.
Zydus Pathline Ltd.
|
PROJECT AT A GLANCE
COST OF PROJECT |
MEANS OF FINANCE |
Particulars |
Existing |
Proposed |
Total |
Particulars |
Existing |
Proposed |
Total |
Land & Site Development Exp. |
********** |
********** |
********** |
Capital |
********** |
********** |
********** |
Buildings |
********** |
********** |
********** |
Share Premium |
********** |
********** |
********** |
Plant & Machineries |
********** |
********** |
********** |
Other Type Share Capital |
********** |
********** |
********** |
Motor Vehicles |
********** |
********** |
********** |
Reserves & Surplus |
********** |
********** |
********** |
Office Automation Equipments |
********** |
********** |
********** |
Cash Subsidy |
********** |
********** |
********** |
Technical Knowhow Fees & Exp. |
********** |
********** |
********** |
Internal Cash Accruals |
********** |
********** |
********** |
Franchise & Other Deposits |
********** |
********** |
********** |
Long/Medium Term Borrowings |
********** |
********** |
********** |
Preliminary& Pre-operative Exp |
********** |
********** |
********** |
Debentures / Bonds |
********** |
********** |
********** |
Provision for Contingencies |
********** |
********** |
********** |
Unsecured Loans/Deposits |
********** |
********** |
********** |
Margin Money - Working Capital |
********** |
********** |
********** |
|
********** |
********** |
********** |
TOTAL |
********** |
********** |
********** |
TOTAL |
********** |
********** |
********** |
COST OF PROJECT
Particulars |
Existing |
Proposed |
Total |
C O S T O F P R O J E C T |
|
|
|
Land & Site Development Exp. |
|
|
|
Land Area Required |
********** |
********** |
********** |
Land Development Cost, Boundary Wall, Gate & Road etc. |
********** |
********** |
********** |
|
********** |
********** |
********** |
Buildings |
********** |
********** |
********** |
Factory Building - |
********** |
********** |
********** |
Office Buildings |
********** |
********** |
********** |
|
********** |
********** |
********** |
Plant & Machineries |
********** |
********** |
********** |
Indigenous Machineries |
********** |
********** |
********** |
Erection & Installation |
********** |
********** |
********** |
Laboratory Equipments |
********** |
********** |
********** |
Miscellaneous Equipments like pumps, valves, pipeline & fittings
|
********** |
********** |
********** |
Imported Machineries |
********** |
********** |
********** |
Technical know how |
********** |
********** |
********** |
|
********** |
********** |
********** |
Office Vehicles |
********** |
********** |
********** |
Office Automation Equipments (Telephone/ Fax/ Computer) |
********** |
********** |
********** |
Office Equipment, Furniture plus Other Equipment & Accessories
|
********** |
********** |
********** |
Other Misc. Assets |
********** |
********** |
********** |
Pre-operative & Preliminary Expenses |
********** |
********** |
********** |
Provision for Contingencies |
********** |
********** |
********** |
|
********** |
********** |
********** |
Total Capital Cost of Project |
********** |
********** |
********** |
Margin Money for Working Capital |
********** |
********** |
********** |
Total Cost of Project |
********** |
********** |
********** |
PROFITABILITY AND NET CASH ACCRUALS
Particulars |
Operating Years
|
|
1-2
|
2-3
|
3-4
|
4-5
|
5-6
|
|
********** |
********** |
********** |
********** |
********** |
Revenue/Income/Realisation |
********** |
********** |
********** |
********** |
********** |
Gross Sales Realisation |
********** |
********** |
********** |
********** |
********** |
Less : Excise Duties/Levies |
********** |
********** |
********** |
********** |
********** |
Net Sales Realisation |
********** |
********** |
********** |
********** |
********** |
Total Revenue/Income/Realisation |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Expenses/Cost of Products/Services/Items |
********** |
********** |
********** |
********** |
********** |
Raw Material Cost |
********** |
********** |
********** |
********** |
********** |
Indigenous |
********** |
********** |
********** |
********** |
********** |
Total Nett Consumption |
********** |
********** |
********** |
********** |
********** |
Lab & ETP Chemical Cost |
********** |
********** |
********** |
********** |
********** |
Packing Material Cost |
********** |
********** |
********** |
********** |
********** |
Sub Total of Net Consumption |
********** |
********** |
********** |
********** |
********** |
Miscellaneous Cost |
********** |
********** |
********** |
********** |
********** |
Employees Expenses |
********** |
********** |
********** |
********** |
********** |
Fuel Expenses |
********** |
********** |
********** |
********** |
********** |
Power/Electricity Expenses |
********** |
********** |
********** |
********** |
********** |
Depreciation |
********** |
********** |
********** |
********** |
********** |
Royalty & Other Charges |
********** |
********** |
********** |
********** |
********** |
Repairs & Maintenance Exp. |
********** |
********** |
********** |
********** |
********** |
Other Mfg. Expenses |
********** |
********** |
********** |
********** |
********** |
Cost of Output of Goods Sold |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Gross Profit |
********** |
********** |
********** |
********** |
********** |
Administration Expenses |
********** |
********** |
********** |
********** |
********** |
Technical Knowhow Fees & Exp. |
********** |
********** |
********** |
********** |
********** |
Financial Charges |
********** |
********** |
********** |
********** |
********** |
Long/Medium Term Borrowing |
********** |
********** |
********** |
********** |
********** |
On Wkg. Capital Borrowings |
********** |
********** |
********** |
********** |
********** |
Total Financial Charges |
********** |
********** |
********** |
********** |
********** |
Selling Expenses |
********** |
********** |
********** |
********** |
********** |
Total Cost of Sales |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Net Profit Before Taxes |
********** |
********** |
********** |
********** |
********** |
Tax on Profit |
********** |
********** |
********** |
********** |
********** |
Net Profit After Taxes |
********** |
********** |
********** |
********** |
********** |
Depreciation Added Back |
********** |
********** |
********** |
********** |
********** |
Technical Knowhow Fees & Exp. |
********** |
********** |
********** |
********** |
********** |
Net Cash Accruals |
********** |
********** |
********** |
********** |
********** |
ASSSESSEMENT OF WORKING CAPITAL REQUIREMENTS
Particulars |
Stk.Prd. |
Stk.Prd. |
|
Operating Years |
|
1st Year |
2nd Yr&+ |
|
1-2 |
2-3 |
3-4 |
4-5 |
5-6 |
Capacity |
Months |
Months |
% |
********** |
********** |
********** |
********** |
********** |
CURRENT ASSETS |
|
|
|
********** |
********** |
********** |
********** |
********** |
Stocks on Hand |
|
|
|
********** |
********** |
********** |
********** |
********** |
Raw Material Cost |
|
|
|
********** |
********** |
********** |
********** |
********** |
Indigenous |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Lab & ETP Chemical |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Packing Material |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Consumable Store |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Work-in-Process |
********** |
********** |
D |
********** |
********** |
********** |
********** |
********** |
Finished Goods |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Current Expenses |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
Receivables |
********** |
********** |
M |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Total |
|
|
|
********** |
********** |
********** |
********** |
********** |
Cash/Bank Balances |
|
|
|
********** |
********** |
********** |
********** |
********** |
Gross Wkg. Capital |
|
|
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
|
|
PROFITABILITY RATIOS, DSCR, DEBT EQUITY
Particulars |
|
Operating Years |
|
|
1-2 |
2-3 |
3-4 |
4-5 |
5-6 |
|
|
|
|
|
|
|
Profit Percentages to Net Sales |
|
|
|
|
|
|
Gross Profit |
|
********** |
********** |
********** |
********** |
********** |
% Of G.P. to Net Sales |
|
********** |
********** |
********** |
********** |
********** |
Net Profit Before Taxes |
|
********** |
********** |
********** |
********** |
********** |
% of N.P.B.T. To Net Sales |
|
********** |
********** |
********** |
********** |
********** |
Net Profit After Taxes |
|
********** |
********** |
********** |
********** |
********** |
% of N.P.A.T. To Net Sales |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
Debt Service Coverage Ratio |
|
|
|
|
|
|
Funds Available to Service Debts |
|
|
|
|
|
|
Net Profit After Taxes |
|
********** |
********** |
********** |
********** |
********** |
Depreciation Charges |
|
********** |
********** |
********** |
********** |
********** |
Technical Knowhow Fees & Exp |
|
********** |
********** |
********** |
********** |
********** |
Interest on Long/Medium Term |
|
********** |
********** |
********** |
********** |
********** |
T o t a l |
|
********** |
********** |
********** |
********** |
********** |
Debt Service Obligations |
|
|
|
|
|
|
Repayment of Long/Medium Ter |
|
********** |
********** |
********** |
********** |
********** |
Interest on Long/Medium Term |
|
********** |
********** |
********** |
********** |
********** |
T o t a l |
|
********** |
********** |
********** |
********** |
********** |
|
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Individual) |
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Cumulative) ..... |
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Overall) ........ |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
Parameters |
|
|
|
|
|
|
Initial Equity Capital |
********** |
********** |
********** |
********** |
********** |
********** |
Credit Balance in P & L |
********** |
********** |
********** |
********** |
********** |
********** |
Total Capital excl Unsec Deposits |
********** |
********** |
********** |
********** |
********** |
********** |
Unsecured Dep. |
********** |
********** |
********** |
********** |
********** |
********** |
Total Equity incl Unsecured Deposits |
********** |
********** |
********** |
********** |
********** |
********** |
Long/Medium Term Borrowings from Bank |
********** |
********** |
********** |
********** |
********** |
********** |
Term lia. Incl Unsecured Deposit |
********** |
********** |
********** |
********** |
********** |
********** |
Total Liabilities |
********** |
********** |
********** |
********** |
********** |
********** |
Total Liabilities incl Unsecured Deposits |
********** |
********** |
********** |
********** |
********** |
********** |
DEBT EQUITY RATIO considering |
|
|
|
|
|
|
i.e.Total Term Lia./NW |
|
|
|
|
|
|
Unsecured Dep. as Equity |
********** |
********** |
********** |
********** |
********** |
********** |
Unsecured Dep. as Debt |
********** |
********** |
********** |
********** |
********** |
********** |
Total Outside Lia./NW |
|
********** |
********** |
********** |
********** |
********** |
Assets Turnover Ratio (x) |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
No. of Shares of 10.00 each |
|
********** |
********** |
********** |
********** |
********** |
Earnings Per Share (EPS) (in `) |
|
********** |
********** |
********** |
********** |
********** |
Proposed divident |
|
********** |
********** |
********** |
********** |
********** |
Cash EPS (in `) |
|
********** |
********** |
********** |
********** |
********** |
Dividend Per Share(DPS) (in `) |
|
********** |
********** |
********** |
********** |
********** |
Payout Ratio (%Age) |
|
********** |
********** |
********** |
********** |
********** |
Retained Earnings/Share (in `) |
|
********** |
********** |
********** |
********** |
********** |
Retained Earnings (%Age) |
|
********** |
********** |
********** |
********** |
********** |
Book Value Per Share (in `) |
|
********** |
********** |
********** |
********** |
********** |
Debt Per Share (in `) |
|
********** |
********** |
********** |
********** |
********** |
Probable Mkt.Price/Share(in `) |
|
********** |
********** |
********** |
********** |
********** |
Price / Book Value (x) |
|
********** |
********** |
********** |
********** |
********** |
Price Earnings Ratio (x) |
|
********** |
********** |
********** |
********** |
********** |
Yield (%Age) |
|
********** |
********** |
********** |
********** |
********** |
BREAK EVEN ANALYSIS
Particulars |
|
Operating Years |
|
Ratio |
1-2 |
2-3 |
3-4 |
4-5 |
5-6 |
|
|
|
|
|
|
|
BREAK EVEN ANALYSIS |
|
|
|
|
|
|
Total Value of Output |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
Variable Cost & Expenses |
|
|
|
|
|
|
Raw Material Cost |
********** |
********** |
********** |
********** |
********** |
********** |
Lab & ETP Chemical Cost |
********** |
********** |
********** |
********** |
********** |
********** |
Packing Material Cost |
********** |
********** |
********** |
********** |
********** |
********** |
Sales Commission/Exp. |
********** |
********** |
********** |
********** |
********** |
********** |
Sub-total |
|
********** |
********** |
********** |
********** |
********** |
Less:W.I.P. Adjustments |
|
********** |
********** |
********** |
********** |
********** |
Total Variable Cost |
|
********** |
********** |
********** |
********** |
********** |
Net Contribution |
|
********** |
********** |
********** |
********** |
********** |
Profit Volume Ratio (%) |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
Semi-Var./Semi-Fixed Exp. |
|
|
|
|
|
|
Miscellaneous Cost |
********** |
********** |
********** |
********** |
********** |
********** |
Employees Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Power/Electricity Expen |
********** |
********** |
********** |
********** |
********** |
********** |
Fuel Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Royalty & Other Charges |
********** |
********** |
********** |
********** |
********** |
********** |
Repairs & Maintenance E |
********** |
********** |
********** |
********** |
********** |
********** |
Other Mfg. Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Administration Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Selling Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Interest on Wkg.Capital |
********** |
********** |
********** |
********** |
********** |
********** |
Tot.Semi-Var./Fixed Exp. |
|
********** |
********** |
********** |
********** |
********** |
|
|
********** |
|
|
|
|
Fixed Expenses / Cost |
|
********** |
|
|
|
|
Miscellaneous Cost |
********** |
********** |
********** |
********** |
********** |
********** |
Employees Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Power/Electricity Expen |
********** |
********** |
********** |
********** |
********** |
********** |
Fuel Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Royalty & Other Charges |
********** |
********** |
********** |
********** |
********** |
********** |
Repairs & Maintenance E |
********** |
********** |
********** |
********** |
********** |
********** |
Other Mfg. Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Administration Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Selling Expenses |
********** |
********** |
********** |
********** |
********** |
********** |
Intrest-Fixed Borrowing |
********** |
********** |
********** |
********** |
********** |
********** |
Intrest-Working Capital |
********** |
********** |
********** |
********** |
********** |
********** |
Depreciation Charges |
********** |
********** |
********** |
********** |
********** |
********** |
Deferred Expenses W/Off |
********** |
********** |
********** |
********** |
********** |
********** |
Total Fixed Expenses |
|
********** |
********** |
********** |
********** |
********** |
Tot.Fixed/Semi-Fixed Exp |
|
********** |
********** |
********** |
********** |
********** |
Tot.Cash Fixed/SemiFixed |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
Cash Break Even Sales |
|
********** |
********** |
********** |
********** |
********** |
Cash Margin of Safety |
|
********** |
********** |
********** |
********** |
********** |
Break Even Sales |
|
********** |
********** |
********** |
********** |
********** |
Margin of safety |
|
********** |
********** |
********** |
********** |
********** |
|
|
|
|
|
|
|
At Maximum Utilisation : |
Year |
********** |
********** |
********** |
********** |
********** |
(as % of Installed Capacity) |
|
|
|
|
|
|
Cash B.E.P. : |
% |
xx% |
xx% |
xx% |
xx% |
xx% |
B.E.P. : |
% |
xx% |
xx% |
xx% |
xx% |
xx% |
M E A N S O F F I N A N C E
Equity Share Capital |
********** |
********** |
********** |
Others - Preference Share Capital |
********** |
********** |
********** |
Total Equity Share Capital |
********** |
********** |
********** |
|
********** |
********** |
********** |
Long/Medium Term Borrowings |
********** |
********** |
********** |
FROM BANK |
********** |
********** |
********** |
From Other Financial Institutions |
********** |
********** |
********** |
Total Long/Medium Term Borrowings |
********** |
********** |
********** |
|
********** |
********** |
********** |
Total Means of Finance
|
********** |
********** |
********** |
INTEREST AND REPAYMENT ON TERM LOANS
A |
Name of Institution-Bank |
ABC BANK |
|
|
B |
Term Borrowing Amount |
********** |
xx |
|
C |
Repayment Term (Years) |
********** |
Years |
|
D |
Repayment Instalments |
********** |
Instalments |
|
E |
Repayment Commencement |
Year - 0; 3rd Qtr. |
|
|
F |
Rate of Interest(General) |
xxxx% |
p.a. |
|
F |
Rate of Interest(Initial) |
0.00% |
p.a. |
|
G |
Apply Gen. Int. Rate from Year |
x Quarter :: x |
|
|
H |
Interest Calculation |
Quarterly |
|
|
Debt Service Coverage Ratio
Funds Available to Service Debts |
|
|
|
|
|
|
Net Profit After Taxes |
|
********** |
********** |
********** |
********** |
********** |
Depreciation Charges |
|
********** |
********** |
********** |
********** |
********** |
Technical Knowhow Fees & Expenses |
|
********** |
********** |
********** |
********** |
********** |
Interest on Long/Medium Term |
|
********** |
********** |
********** |
********** |
********** |
T o t a l |
|
********** |
********** |
********** |
********** |
********** |
Debt Service Obligations |
|
********** |
********** |
********** |
********** |
********** |
Repayment of Long/Medium Term |
|
********** |
********** |
********** |
********** |
********** |
Interest on Long/Medium Term |
|
********** |
********** |
********** |
********** |
********** |
T o t a l |
|
********** |
********** |
********** |
********** |
********** |
|
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Individual) |
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Cumulative) ..... |
|
********** |
********** |
********** |
********** |
********** |
D. S. C. R. (Overall) ........ |
|
********** |
********** |
********** |
********** |
********** |
DEPRECIATION CHARGES AS PER BOOKS (TOTAL)
Operating Year |
F.Assets Type A-1 |
F.Assets Type A-2 |
F.Assets Type B |
F.Assets Type C |
F.Assets Type D-1 |
F.Assets Type D-2 |
Total |
Particulars |
Factory Building - |
Office Buildings |
PLANT & MACHINERY |
Office Vehicles |
Office Automation Equipments (Telephone/ Fax/ Computer)
|
Furniture & Fixtures |
|
1-2 |
********** |
********** |
********** |
********** |
********** |
********** |
********** |
2-3 |
********** |
********** |
********** |
********** |
********** |
********** |
********** |
3-4 |
********** |
********** |
********** |
********** |
********** |
********** |
********** |
4-5 |
********** |
********** |
********** |
********** |
********** |
********** |
********** |
5-6 |
********** |
********** |
********** |
********** |
********** |
********** |
********** |
Particulars |
Method |
Deprn.Rate |
Part Consideration (for Asset put to use less than xx
months)
|
|
|
|
|
Type A :: Buildings |
|
|
|
|
|
|
|
Factory Building - |
WDV |
********** |
********** |
|
|
|
|
Office Buildings |
WDV |
********** |
********** |
|
|
|
|
Type C |
|
|
|
|
|
|
|
Office Vehicles |
WDV |
********** |
********** |
|
|
|
|
Type D :: Misc. Fixed Assets |
|
|
|
|
|
|
|
Office Automation Equipments (Telephone/ Fax/ Computer) |
WDV |
********** |
********** |
|
|
|
|
Furniture & Fixtures |
WDV |
********** |
********** |
|
|
|
|
Projected Pay Back Period
Particulars |
Operating Years |
|
1-2 |
2-3 |
3-4 |
4-5 |
5-6 |
Year |
1 |
2 |
3 |
4 |
5 |
Initial Investment |
********* |
|
|
|
|
Total Initial Investment |
********* |
|
|
|
|
Yearly Cash Flow |
********* |
********* |
********* |
********* |
********* |
Accumulated Cash Flow |
********* |
********* |
********* |
********* |
********* |
Pay Back Period |
xx Years xx Months |
xx Years xx months |
|
|
Projected IRR
Year |
CFAT |
PV factor @**% |
********* |
Initial Investment |
********* |
********* |
********* |
1-2 |
********* |
********* |
********* |
2-3 |
********* |
********* |
********* |
3-4 |
********* |
********* |
********* |
4-5 |
********* |
********* |
********* |
5-6 |
********* |
********* |
********* |
Total PV |
********* |
|
********* |
IRR |
********* |
|
********* |
|
|
|
|
PROJECTED BALANCE SHEET
Particulars |
Operating Years |
|
1-2 |
2-3 |
3-4 |
4-5 |
5-6 |
|
|
|
|
|
|
Equity Share Capital |
********** |
********** |
********** |
********** |
********** |
Surplus of Previous Year |
********** |
********** |
********** |
********** |
********** |
Add : Net Profit After Taxes |
********** |
********** |
********** |
********** |
********** |
Surplus at the End of Year |
********** |
********** |
********** |
********** |
********** |
Unsecured Deposits |
********** |
********** |
********** |
********** |
********** |
Long/Medium Term Borrowings Proposed-FROM BANK |
********** |
********** |
********** |
********** |
********** |
Bank Borrowing for Wkg. Capital |
********** |
********** |
********** |
********** |
********** |
Current Liabilities |
********** |
********** |
********** |
********** |
********** |
Sundry Creditors |
********** |
********** |
********** |
********** |
********** |
Other Current
Liabilities
|
********** |
********** |
********** |
********** |
********** |
Total Current Liabilities |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Total of Liabilities |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
A S S E T S |
********** |
********** |
********** |
********** |
********** |
Fixed Assets |
********** |
********** |
********** |
********** |
********** |
Gross Block |
********** |
********** |
********** |
********** |
********** |
Less : Depreciation to Date |
********** |
********** |
********** |
********** |
********** |
Net Block |
********** |
********** |
********** |
********** |
********** |
Current Assets |
********** |
********** |
********** |
********** |
********** |
Stocks on Hand |
********** |
********** |
********** |
********** |
********** |
Receivables
|
********** |
********** |
********** |
********** |
********** |
Other Current Assets |
********** |
********** |
********** |
********** |
********** |
Cash and Bank Balances |
********** |
********** |
********** |
********** |
********** |
Total Current Assets |
********** |
********** |
********** |
********** |
********** |
P & P Exp. and/or Other Dvp.Exp. |
********** |
********** |
********** |
********** |
********** |
(To The Extent Not W/Off) |
********** |
********** |
********** |
********** |
********** |
Other Non Current Assets |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
Total of Assets |
********** |
********** |
********** |
********** |
********** |
|
********** |
********** |
********** |
********** |
********** |
ROI (Average of Fixed Assets) |
********** |
********** |
********** |
********** |
********** |
RONW (Average of Share Capital) |
********** |
********** |
********** |
********** |
********** |
ROI (Average of Total Assets) |
********** |
********** |
********** |
********** |
********** |
COMPANY SUMMARY
NIIR PROJECT CONSULTANCY SERVICES (NPCS)is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.
Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.
NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.
REASONS FOR BUYING THE REPORT
- This report helps you to identify a profitable project for investing or diversifying into by throwing light to crucial areas like industry size, demand of the product and reasons for investing in the product.
- This report provides vital information on the product like its definition, characteristics and segmentation.
- This report helps you market and place the product correctly by identifying the target customer group of the product.
- This report helps you understand the viability of the project by disclosing details like raw materials required, manufacturing process, project costs and snapshot of other project financials.
- The report provides forecasts of key parameters which helps to anticipate the industry performance and make sound business decision.
OUR APPROACH
- Our research reports broadly cover Indian markets, present analysis, outlook and forecast.
- The market forecasts are developed on the basis of secondary research and are cross-validated through interactions with the industry players.
- We use reliable sources of information and databases. And information from such sources is processed by us and included in the report.
TABLE OF CONTENT
Introduction
Project Introduction
Project Objective and Strategy
Concise History of the Product
Properties
BIS (Bureau of Indian Standards) Provision & Specification
Uses & Applications
Market Study and Assessment
Current Indian Market Scenario
Present Market Demand and Supply
Estimated Future Market Demand and Forecast
Statistics of Import & Export
Names & Addresses of Existing Units (Present Players)
Market Opportunity
Raw Material
List of Raw Materials
Properties of Raw Materials
Prescribed Quality of Raw Materials
List of Suppliers and Manufacturers
Personnel (Manpower) Requirements
Requirement of Staff & Labor (Skilled and Unskilled) Managerial,
Technical, Office Staff and Marketing Personnel
Plant and Machinery
List of Plant & Machinery
Miscellaneous Items
Appliances & Equipments
Laboratory Equipments & Accessories
Electrification
Electric Load & Water
Maintenance Cost
Sources of Plant & Machinery (Suppliers and Manufacturers)
Manufacturing Process and Formulations
Detailed Process of Manufacture with Formulation
Packaging Required
Process Flow Sheet Diagram
Infrastructure and Utilities
Project Location
Requirement of Land Area
Rates of the Land
Built Up Area
Construction Schedule
Plant Layout and Requirement of Utilities
FINANCIAL PLAN
Assumptions for Profitability workings |
Plant Economics |
Production Schedule |
Land & Building
- Factory Land & Building
- Site Development Expenses
|
Plant & Machinery
- Indigenous Machineries
- Other Machineries (Miscellaneous, Laboratory etc.)
|
Other Fixed Assets
- Furniture & Fixtures
- Pre-operative and Preliminary Expenses
- Technical Knowhow
- Provision of Contingencies
|
Working Capital Requirement Per Month
- Raw Material
- Packing Material
- Lab & ETP Chemical Cost
- Consumable Store
|
Overheads Required Per Month And Per Annum
- Utilities & Overheads (Power, Water and Fuel Expenses etc.)
- Royalty and Other Charges
- Selling and Distribution Expenses
|
Salary and Wages
|
Turnover Per Annum
|
Share Capital
- Equity Capital
- Preference Share Capital
|
Annexure 1:: Cost of Project and Means of Finance
|
Annexure 2:: Profitability and Net Cash Accruals
- Revenue/Income/Realisation
- Expenses/Cost of Products/Services/Items
- Gross Profit
- Financial Charges
- Total Cost of Sales
- Net Profit After Taxes
- Net Cash Accruals
|
Annexure 3 :: Assessment of Working Capital requirements
- Current Assets
- Gross Working. Capital
- Current Liabilities
- Net Working Capital
- Working Note for Calculation of Work-in-process
|
Annexure 4 :: Sources and Disposition of Funds
|
Annexure 5 :: Projected Balance Sheets
- ROI (Average of Fixed Assets)
- RONW (Average of Share Capital)
- ROI (Average of Total Assets)
|
Annexure 6 :: Profitability ratios
- D.S.C.R
- Earnings Per Share (EPS)
- Debt Equity Ratio
|
Annexure 7 :: Break-Even Analysis
- Variable Cost & Expenses
- Semi-Var./Semi-Fixed Exp.
- Profit Volume Ratio (PVR)
- Fixed Expenses / Cost
- B.E.P
|
Annexure 8 to 11:: Sensitivity Analysis-Price/Volume
- Resultant N.P.B.T
- Resultant D.S.C.R
- Resultant PV Ratio
- Resultant DER
- Resultant ROI
- Resultant BEP
|
Annexure 12 :: Shareholding Pattern and Stake Status
- Equity Capital
- Preference Share Capital
|
Annexure 13 :: Quantitative Details-Output/Sales/Stocks
- Determined Capacity P.A of Products/Services
- Achievable Efficiency/Yield % of Products/Services/Items
- Net Usable Load/Capacity of Products/Services/Items
- Expected Sales/ Revenue/ Income of Products/ Services/ Items
|
Annexure 14 :: Product wise domestic Sales Realisation |
Annexure 15 :: Total Raw Material Cost |
Annexure 16 :: Raw Material Cost per unit |
Annexure 17 :: Total Lab & ETP Chemical Cost |
Annexure 18 :: Consumables, Store etc., |
Annexure 19 :: Packing Material Cost |
Annexure 20 :: Packing Material Cost Per Unit |
Annexure 21 :: Employees Expenses |
Annexure 22 :: Fuel Expenses |
Annexure 23 :: Power/Electricity Expenses |
Annexure 24 :: Royalty & Other Charges |
Annexure 25 :: Repairs & Maintenance Exp. |
Annexure 26 :: Other Mfg. Expenses |
Annexure 27 :: Administration Expenses |
Annexure 28 :: Selling Expenses |
Annexure 29 :: Depreciation Charges – as per Books (Total) |
Annexure 30 :: Depreciation Charges – as per Books (P & M) |
Annexure 31 :: Depreciation Charges - As per IT Act WDV (Total) |
Annexure 32 :: Depreciation Charges - As per IT Act WDV (P & M) |
Annexure 33 :: Interest and Repayment - Term Loans |
Annexure 34 :: Tax on Profits |
Annexure 35 ::Projected Pay-Back Period And IRR |
INFORMATION/ DISCLAIMER
- One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
- One Crore is equivalent to ten million (10,000,000)
- T.C.I is Total Capital Investment
- We can modify the project capacity and project cost as per your requirement.
- We can also prepare project report on any subject as per your requirement.
- Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.